Condition: Metastatic Cancers · Advanced Cancers · Cancers That Cannot be Treated With Curative Intent · Sponsor: British Columbia Cancer Agency
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.
This description comes directly from the study's public registry record.
Janessa J Laskin, MD · jlaskin@bccancer.bc.ca
Marco Marra, PhD · mmarra@bcgsc.ca
Always discuss trial participation with your own doctor first.
| BC Cancer Agency | Vancouver, British Columbia, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02155621